Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis.

Wang FM, Yu F, Tan Y, Song D, Zhao MH.

Rheumatology (Oxford). 2012 Dec;51(12):2269-77. doi: 10.1093/rheumatology/kes218. Epub 2012 Sep 6.

PMID:
22956549
2.

Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis.

Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH.

Nephrol Dial Transplant. 2009 Jan;24(1):172-8. doi: 10.1093/ndt/gfn453. Epub 2008 Aug 12.

PMID:
18697800
3.

Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis.

Hung WT, Chen YM, Lan JL, Chen HH, Chen YH, Chen DY, Hsieh CW, Wen MC.

Lupus. 2011 Nov;20(13):1404-10. doi: 10.1177/0961203311417033. Epub 2011 Sep 26.

PMID:
21946514
4.

[The roles of complement 1q and anti-C1q autoantibodies in pathogenesis of lupus nephritis].

Zhang FC, Zhou B, Dong Y.

Zhonghua Yi Xue Za Zhi. 2005 Apr 13;85(14):955-9. Chinese.

PMID:
16061001
5.

Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis.

Chen DY, Hsieh CW, Chen KS, Chen YM, Lin FJ, Lan JL.

Lupus. 2009 Jan;18(1):29-37. doi: 10.1177/0961203308094559.

PMID:
19074166
6.

Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.

Batal I, Liang K, Bastacky S, Kiss LP, McHale T, Wilson NL, Paul B, Lertratanakul A, Ahearn JM, Manzi SM, Kao AH.

Lupus. 2012 Jan;21(1):13-26. doi: 10.1177/0961203311422093. Epub 2011 Sep 29.

PMID:
21959138
7.

Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study.

Manson JJ, Ma A, Rogers P, Mason LJ, Berden JH, van der Vlag J, D'Cruz DP, Isenberg DA, Rahman A.

Arthritis Res Ther. 2009 Oct 14;11(5):R154. doi: 10.1186/ar2831.

8.

Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus.

El-Banawy HS, Gaber EW, Maharem DA, Matrawy KA.

J Nephrol. 2012 Jul-Aug;25(4):541-50. doi: 10.5301/jn.5000030.

PMID:
21956768
9.

Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus.

Yip J, Aghdassi E, Su J, Lou W, Reich H, Bargman J, Scholey J, Gladman DD, Urowitz MB, Fortin PR.

J Rheumatol. 2010 Aug 1;37(8):1667-72. doi: 10.3899/jrheum.091028. Epub 2010 Jun 1.

PMID:
20516026
10.

Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis.

Tan Y, Song D, Wu LH, Yu F, Zhao MH.

BMC Nephrol. 2013 Mar 19;14:63. doi: 10.1186/1471-2369-14-63.

11.

Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.

Brugos B, Kiss E, Dul C, Gubisch W, Szegedi G, Sipka S, Zeher M.

Hum Immunol. 2010 Sep;71(9):874-7. doi: 10.1016/j.humimm.2010.06.004. Epub 2010 Jun 9.

PMID:
20538031
12.

Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.

Pradhan VD, Patwardhan MM, Ghosh K.

Indian J Dermatol Venereol Leprol. 2010 Mar-Apr;76(2):145-9. doi: 10.4103/0378-6323.60558.

13.

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C.

Arthritis Res Ther. 2009;11(5):R143. doi: 10.1186/ar2816. Epub 2009 Sep 28.

14.

Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.

Oelzner P, Deliyska B, Fünfstück R, Hein G, Herrmann D, Stein G.

Clin Rheumatol. 2003 Oct;22(4-5):271-8.

PMID:
14576989
15.

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus.

Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Rönnblom L, Nordmark G, Sturfelt G, Blom AM.

Arthritis Res Ther. 2011;13(6):R206. doi: 10.1186/ar3539. Epub 2011 Dec 15.

16.

Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis.

Alzawawy A, Zohary M, Ablordiny M, Eldalie M.

Int J Rheum Dis. 2009 Dec;12(4):311-8. doi: 10.1111/j.1756-185X.2009.01429.x.

PMID:
20374368
17.

Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.

Cohen D, Koopmans M, Kremer Hovinga IC, Berger SP, Roos van Groningen M, Steup-Beekman GM, de Heer E, Bruijn JA, Bajema IM.

Arthritis Rheum. 2008 Aug;58(8):2460-9. doi: 10.1002/art.23662.

18.

Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis.

Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D'Cruz D, Hughes GR.

Ann Rheum Dis. 2003 Jun;62(6):556-60.

19.

Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis.

Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, Song YW.

Lupus. 2009 Jan;18(1):22-8. doi: 10.1177/0961203308094361.

PMID:
19074165
20.

[Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].

Cai XY, Yang XY, Chen XH, Liang LQ, Guan MM, Qin SG, Fu JZ.

Zhonghua Yi Xue Za Zhi. 2004 Sep 2;84(17):1436-9. Chinese.

PMID:
15500738

Supplemental Content

Support Center